monarchE Study

The monarchE study is a randomized, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of abemaciclib combined with endocrine therapy versus endocrine therapy alone in HR+, HER2-high-risk early-stage breast cancer patients. Since the disclosure of relevant data in March 2020, the study results have been updated multiple times, establishing the standard position of abemaciclib combined with endocrine therapy. At the 2023 ESMO Congress, Professor Nadia Harbeck, the lead investigator of the monarchE study from the University of Munich, Germany, announced the milestone data results of the 5-year follow-up. In this regard, Professor Zhimin Shao, the lead investigator of the monarchE study, director of the Institute of Oncology and Institute of Breast Cancer Research at Fudan University, and director of the Department of Surgery at Fudan University Affiliated Tumor Hospital, provided an introduction and interpretation of the monarchE study results.